Neurodegeneration: Potential Causes, Prevention, and Future Treatment Options by Zhongtao Zhang
  
Neurodegeneration: Potential Causes, Prevention, and Future 
Treatment Options 
 
Zhongtao Zhang 
New York Medical College  
Valhalla, NY 10595 
Here I advance a hypothesis that neurodegeneration is a natural process associated with aging due to the 
loss of genetic redundancy following a mathematical model R(t) = R0(1-αe(βC+γI+δEt)t), where the calorie 
intake (C) and immune response (I) play critical roles. The early onset of neurodegenerative diseases such 
as Alzheimer’s disease is due to metabolic imbalance or chronic immune reactions to various infections. 
Therefore, the potential treatment options for neurodegenerative diseases are to modulate metabolism and 
immune response. 
Age related neurological disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) exert 
tremendous social and economic strain on society. The World Alzheimer Report 2010 estimated that worldwide 
economic cost of age-related dementia is over $600 billion annually, and predicted it will rise rapidly in the near 
future. Even though scientific research in academic and industrial settings has made significant progress in 
understanding the basis of neurodegeneration, the development of disease-modifying treatment options lags 
behind. The majority of treatments in development for AD funded by public and private sources are based on the 
β-amyloid cascade hypothesis1, 2. However, late-stage clinical trials based on this hypothesis have not been 
successful, such as Semagacestat  (bace 1 inhibitor)3, 4 from Eli Lilly and earlier immunotherapy from Elan 
Pharmaceuticals5. In addition, there are hundreds of current clinical studies targeting the same pathway by 
reduction of β-amyloid load or its accumulation. This begs the critical question: will the reduction of β-amyloid 
burdens result in the slowing-down of neurodegeneration? Here we propose a novel hypothesis regarding the 
cause of neurodegeneration which implies alterative treatment options. It is imperative for society as a whole to 
pool resources to solve the urgent needs of an aging worldwide population. Therefore, where and how to use the 
limited resource becomes an increasingly important question. 
HYPOTHESIS 
Aging is the result of the reduction of genetic redundancy due to accumulated cellular damage from free 
radicals. These free radicals come from two main sources, metabolic process and immune response, as well as 
a secondary source, the environment.  
The proposed mechanism of DNA damage is especially true for neurons, since differentiated cells do not replicate 
or undergo replication repair and the genetic errors cannot come from DNA replication. In addition, the implied 
reduction in genetic redundancy not only originates from direct DNA damage, but also comes from damage to 
other cellular components, as this damage can reduce cell’s ability or accuracy to transcribe or translate the 
genetic information. Two major sources of free radicals, metabolism6 (mitochondria respiration) and immune 
response7 are unavoidable and therefore, life is destined to age. 
Combining this hypothesis with the free radical theory of aging8, the reliability theory of aging9, 10 and the 
Gompertz-Makeham11, 12 law of mortality, we can arrive at a mathematic equation of neuronal aging: 
R(t) = R0(1-αe(βC+γI+δEt)t) 
R(t): redundancy at time t; R0, initial redundancy; α, frequency of redundancy loss by free radical hits; β, free 
radical index of calories; C, amount of calorie; γ, free radical index from immune responses; I, quantitative 
immune response; δ, environmental impact index; E, quantitative environmental impact; t, time. 
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We have two copies of each chromosome; therefore, the initial redundancy (R0) for females is close to 2 and for 
males, it is close to 1.95. The loss of redundancy in 
males is due to the loss of genes in Y chromosome 
during evolution. Even though we have not elucidated 
the various constants and the time factors for calorie 
intake and the immune response, the implications of 
this mathematical model are not diminished. In 
majority of individuals, the impact from calorie intake 
and immune response dominate and the environmental 
factors are hard to quantify. However, the 
environmental impact can dominate in extreme cases 
because of the time factor (Et),  such as via repeated 
head trauma or prolonged exposure to heavy metals. 
Similarly, positive environmental factors can provide 
added protection, giving some individuals with 
extraordinary life expectancies and sharp mental 
acuity late in life. In addition, the weight distribution 
between calorie impact and immune response varies 
with time as well. Most likely the immune responses 
increase impact as we age. Figure 1 illustrates the 
aging curve assuming an average environmental 
impact (E=0). Currently we do not know when the 
onset of the disease begins (R(t) equals 1.5 or 1.0?). 
However, 16% reduction of the combined impact from caloric and immune response throughout life could delay 
the onset of age-related dementia by more than a decade (Fig.1). 
The initial redundancy differences between male and female do not result in significant differences in neuronal 
aging rate late in life (Fig.2). However, because women have longer life expectancies in developed countries, they 
might be more susceptible to developing AD.  On the other hand, the initial redundancy differences between sexes 
are large enough to make males more susceptible to 
environmental factors early in life.  
POTENTIAL CAUSES OF ALZHEIMER’S DISEASE 
The β-amyloid cascade theory has dominated the research 
and development field in Alzheimer’s disease for the last 
two decades, although scientists have begun to be aware of 
the metabolic connection, especially the connection between 
type II diabetes and Alzheimer’s disease13. Then what are the 
causes of Alzheimer’s disease? Our hypothesis would 
suggest that AD is intricately associated with age and one 
can suggest that AD is almost unavoidable if an individual 
lives long enough. Then why do some individuals get the 
disease earlier? Our theory suggests that there are two 
possible causes of Alzheimer’s disease besides those rare 
cases due to genetic mutations. 
  
Majority of cases are the results of metabolic disorders. 
From the equation R(t) = R0(1-αe(βC+γI+δEt)t), the metabolic 
term has two factors. The amount of calorie (C) plays the 
most important role, as an increased calorie intake will 
inevitably increase the free radical production. The free radical index (β) of calorie includes the quality of calorie 
and the balance of calorie sources (carbohydrates, proteins and fat). The metabolism of carbohydrates is the 
Fig. 1. Reduction of calorie and immune esponse 
can slow down neurodegeneration. Hypothetical 
plots of the redundancy decline with equation R(t) 
= 2(1-0.003e0.06t) (red) and R(t) = 2(1-0.003e0.05t) 
(green). 
Fig. 2. Initial redundancy differences 
between male and female do not result in 
significant differences in the redundancy 
decline later in life. Hypothetical 
equation plotted with R(t) = 2(1-
0.003e0.06t) (green) and R(t) = 1.95(1-
0.003e0.06t) (red). 
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preferred energy source for neurons, as glycolysis can generate energy (ATP) without producing free radicals, 
whereas the metabolism of proteins and fatty acids can only be accomplished through mitochondria oxidation. 
Therefore, diet with high fat content will cause increased rates of neuronal aging. Consequently, majority of cases 
of Alzheimer’s most likely arise from the imbalance between glycolysis and mitochondria oxidative 
phosphorylation due to dietary imbalance throughout life. In addition, the free radical index of calorie could vary 
among individuals due to genetic variations and life-style differences. 
Some cases could be the results of chronic infection, 
especially from these pathogens that can infiltrate the 
central nervous system (CNS), as these infections elicit 
persistent immune responses. This aspect still requires 
further research about what types of pathogens can 
penetrate the relative immune privilege of the CNS14. 
Some chronic infections caused by prions15, bacteria 
such as Borrelia burgdorferi (Lyme disease)16-18, or 
viruses such as Herpes simplex virus19 can infiltrate the 
brain and elicit persistent immune reactions. These cases 
could possibly be treated with antiviral or antibacterial 
agents if diagnosed early enough. The connection of AD 
with other immunological disorders, such as 
autoimmune diseases, still requires further investigation. 
TREATMENT OPTIONS 
 
Our hypothesis has profound implications in the 
development of disease modifying treatment options. The key to slowdown neurodegeneration is to reduce the 
production of free radicals either from modulation of immune responses or mitochondria respiration or the 
combination of both. The mathematical model can provide some guideline for the design of treatment strategies. 
Let’s assume that the onset of AD is the result of reduction of redundancy to 1.0 and the symptoms appear when 
the redundancy is at 1.5. If we start treatments that reduce the combined impact of calorie and immune response 
by 16%, we could delay the disease onset by about three years (Fig.3). How far can we delay the disease onset 
exactly remains to be seen. However, it is possible to 
delay the disease for a decade if we can start the 
optimized treatment regime early enough, which put a 
premium on the early diagnosis. Figure 4 illustrates 
the importance of early diagnosis and treatment. The 
theoretical model assumes that the treatment reduces 
the free radical impact by 33% (R(t) = 2(1-0.003e0.06t) 
in comparison with R(t) = 2(1-0.003e0.04t)). Starting 
treatment at R(t) value of 1.75 or 1.5 makes a 
significant difference (Fig.4). 
 
A: Immune  Modulation. 
 
Dietary restrictions are generally difficult to adhere to 
for physicians as well as for patients. However, 
immune modulation has been used successfully for the 
treatment of various diseases such as arthritis, Crohn’s 
disease, organ transplantation and others20. These 
medications have a relatively good safety profiles and 
should be explored for the treatment of Alzheimer’s 
diseases. Recent development of monoclonal 
antibodies for the modulation of immune responses is 
Fig. 3. Reduction of calorie or immune impact 
by 16% (green line) upon diagnosis could 
delay disease onset by about 3 years 
Fig. 4 Early diagnosis and treatment initiation 
are critical to delay the onset of disease. Starting 
treatment at R(t) of 1.75 (blue line) or 1.5 (green 
line) makes significant difference 
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especially interesting, since they have defined targets, an established safety profile and characterized mechanism 
of action. We project that monoclonal antibodies against TNF alpha or beta, IL-1, IL-2, IL-6, and IL-12 should all 
have significant activities towards treating Alzheimer’s disease. Small molecule immune modulators could have 
the desired therapeutic value as well. Inhibitors in the TNF-alpha pathway, immune suppressants (currently used 
in transplantation), estriol, and even moderate concentrations of steroids could also exhibit disease modifying 
activities. We project that optimal immune modulation can delay the onset of AD by three to five years. It is 
imperative that clinical trials be conducted as soon as possible for these novel approaches.  
 
Undoubtedly, immune suppression will have significant side effects, such as increased risk of cancer and various 
infections. However, the benefit most likely is much greater than the risk, especially since many immune 
modulators have been in clinical applications for a significant period of time. 
 
B. Metabolism Modulation 
 
Effective small molecule metabolism regulators have not been discovered. The targets for slowing down neuronal 
aging are two-fold. The first option is to slowdown mitochondria activity, especially neuronal mitochondria 
activity, without depleting energy supply to neurons. The second option is to facilitate the neuronal glycolysis. 
Evidently, these goals are difficult to achieve, as they could be contradictory at times. Here we would like to 
suggest a number of targets for the development of future therapeutic options. 
 
Mitochondria activity regulators.  
 
Many enzymes regulate mitochondria metabolite flow. The critical requirement is to regulate mitochondria 
activity without the accumulation of the reactive intermediate metabolites that can generate free radicals, such as 
semiquinones. One possible option is to restrict the supply of ubiquinone by limiting its biosynthesis. The human 
enzyme COQ7 (c elegans clk-1 homolog) could be an interesting target as it is required for the synthesis of 
ubiquinone21. However, development of inhibitors for this enzyme is a difficult task, as robust inhibition could 
lead to many diseases, even neurodegeneration, as it could limit the energy supply to neurons. The ideal inhibitor 
would be a non-competitive inhibitor (hopefully reducing the Vmax by 25 to 50%) without changing the affinity 
for its substrate. The other option would be to increase the mitochondria activity for non-neuronal cells, as these 
cells can metabolize the non-carbohydrate and glycolysis metabolites from neurons. The combination could 
facilitate neurons to generate more of their energy from glycolysis. Aside from exercise, few other options can 
reach this goal. 
 
Another possible option is to regulate the free iron concentration in neurons, because Clk-1 homologs all require 
iron for activity. However, it is a challenge to limit iron concentrations in neurons alone. 
Most importantly, our hypothesis suggests that popular supplements such as coenzyme Q10 which could facilitate 
the mitochondria phosphorylation oxidation will not have any positive effect on neurodegeneration. On the 
contrary, it most likely has an adverse effect if there are any. 
 
Glycolysis Facilitators 
 
The goal is to facilitate the neurons using glycolysis as the major energy source without limiting the amount of 
energy produced. Glycolysis in the cytosol is a self-limiting process as it depends on the conversion of NADH 
back to NAD+ through mitochondria or other oxidation reactions to restart glycolysis. Normally neurons can 
carry through the oxidation of glucose to generate ATP both in the cytosol and from mitochondria. However, an 
excess amount of ketone bodies from circulation taken up by the neurons will inhibit the glycolytic process. An 
ideal compound can facilitate the conversion of NADH to NAD+ in the cytosol without generating free radicals. 
Molecules such as thionine derivatives could potentially accomplish such a task. In addition, thionine derivatives 
such as methylene blue can also accelerate the mitochondria electron transport reactions without generating 
semiquinones, which are a source of free radicals22. Therefore, it is not a surprise that methylene blue showed 
some promise in a phase 2 trial for treating Alzheimer’s disease23-25. However, methylene blue is less than ideal, 
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as it can bind many reductases as well as DNA. Further research is required for the identification of more ideal 
compounds. 
 
Many compounds in development aiming to restore the balance of glycolysis and mitochondria phosphorylation 
oxidation for treating type II diabetes could have therapeutic value in Alzheimer’s disease as well, such as GKA 
activators, amylin analogs, and leptin analogs26. There are also many compounds in development to treat obesity 
by regulating calorie intake. All these approaches will impact the developing course of Alzheimer’s disease as 
well. 
 
PREVENTION 
 
Our hypothesis that Alzheimer’s disease is mainly a metabolic disorder implies that it is preventable. The health 
benefits of a balanced low calorie diet are multifaceted. It not only reduces cardiovascular diseases and type II 
diabetes, but it is also the best option for preventing Alzheimer’s disease. A balanced diet low in fat and protein 
not only delays aging in general, but also impedes neuronal aging and development of AD.  
 
Physical exercise also plays an important role in preventing neurodegeneration. The preferred energy source for 
neurons is glucose. However, neuronal glycolysis depends on the uptake of glucose and continued efflux of its 
metabolites. Overdependence of the whole body on fatty acid metabolism will impede the neuronal use of 
glycolysis, as the circulating ketone bodies will supply neurons with excess nutrients. Furthermore, excess energy 
supply will down-regulate the expression of glucose transporters on all organs, which further impedes glucose 
uptake of all cell types. On the other hand, exercise will burn the excess calories and promote the expression of 
glucose transporters in all cell types. In addition, exercise will strengthen the non-neuronal organs and promote 
blood flow. The efflux of metabolites (most likely lactate)27 from glycolysis in neurons can be facilitated by 
improved circulation, and these metabolites can be used for energy by other organs such as a strong heart and 
increased muscle mass28, 29, which in turn will help the neurons to generate more energy from glycolysis. 
Maintaining an active life style by incorporating exercise and a sensible diet will go a long way to maintain one’s 
mental edge. 
 
FUNCTIONS OF PROTEINS INVOLVED IN NEURODEGENERATION 
 
Alzheimer’s Disease 
 
A number of genes whose mutation can cause early onset of Alzheimer’s disease or Parkinson’s disease have 
been identified. In the case of Alzheimer’s disease, three genes coding for protein β-amyloid precursor protein (β-
APP), presenilin 1 and presenilin 2 have been identified to cause early disease onset when there are deleterious 
mutations30. Extensive research on these proteins has reported various functions. Those identified functions 
mostly revolve around the production of amyloid peptides whose aggregation could result in the formation of 
plaques, the hallmark of Alzheimer’s disease. Then how will the functions of β-amyloid fit into our hypothesis? 
Currently, only one target protein has been firmly established to interact with β-amyloid-ABAD (amyloid beta-
peptide-binding alcohol dehydrogenase)31. ABAD is a mitochondria protein involved in the metabolism of short-
chain fatty acid and displays a diversified substrate specificity32. It can oxidize a variety of 17-β-hydroxysteroids 
and plays a role in steroid metabolism. Therefore, β-amyloid peptide has at least two functions: 
 
1. Inhibiting the oxidation of fatty acid metabolites, which would slowdown the mitochondria oxidative 
phosphorylation reactions.  
2. Suppressing the immune response. Through binding to ABAD, β-amyloid peptide will inhibit the 
oxidation of steroid derivatives, which can suppress the immune response. The existence of amyloid 
peptides in the central nervous system could thus contribute to the immune privilege of the brain as well. 
Therefore, the production of amyloid peptides is the response of the central nervous system to reduce the 
production of free radicals from the mitochondria and the immune response. However, genetic mutations resulting 
in the continuous over-production of β-amyloid peptides will impede neuronal cell’s ability to generate enough 
ATP and thus result in early neuronal death. 
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This hypothesis suggests that the current clinical trials that focus on the reduction of β-amyloid peptide 
production most likely will not work, except perhaps in rare genetic cases. We may observe an initial symptom 
relief by limiting the production or increasing the clearance of amyloid peptides due to increased temporary ATP 
production. However, the prolonged exposure to these treatments most likely exacerbates the neurodegeneration 
process and causes brain inflammation due to loss of immune modulation by β-amyloid peptides. 
The other gene that is involved in the increased risk of development of Alzheimer’s disease is apoE isoform of 
apolipoproteins. Our hypothesis is consistent with the current research demonstrating that apoE is most likely 
involved in fatty acid metabolism and immune modulation30. 
 
Parkinson’s disease 
 
Parkinson’s disease is the result of degeneration of dopaminergic neurons in the substantia nigra pars compacta of 
the brain, which results in the decreased production of dopamine33-35. In comparison with Alzheimer’s disease, PD 
involves the early degeneration of a specific region of the brain instead of the global degeneration of the neurons 
for AD. There are also significant similarities at later stages between both diseases36, 37. However, these 
differences imply a more significant genetic role for PD pathogenesis, contrary to the current belief that majority 
of PD cases are sporadic. Our hypothesis suggest that majority of cases of PD are associated with genetic 
variations, whereas only a fraction of cases are due to the environmental factors. This implies that future genetic 
approaches for the treatment of PD are feasible, whereas genetic 
interventions for AD are not very likely to succeed. 
Mutations of many genes can cause early onset of Parkinson’s disease38-
40. These genes code for proteins α-synuclein, DJ-1, Parkin, pink1, Lrrk2, 
UCHL1, ATP13A2, Nurr1, and HtrA2. The reported and proposed 
functions of these proteins vary significantly in the literature and 
consistent integration of these functions is lacking. Our hypothesis 
proposes an integrated pathway for all the park proteins. Collectively, 
Park proteins are involved in the regulation of three functions: 
mitochondria function, oxidative stress sensing, and immune modulation. 
Recent research on the functions of these proteins supports our 
hypothesis that these proteins are involved in regulating mitochondria 
function41, though evidence to link these proteins to immune regulation 
is still lacking. However, the recent genome wide association studies 
linking immune proteins to PD42 lend further support to our hypothesis. 
MECHANISM OF PROTEIN AGGREGATION 
 
Oxidation of biomolecules by reactive oxygen species during aging will 
give rise to ketones, epoxides, and quinones. These moieties are strong 
electrophiles that can react with nucleophiles such as amino groups and 
sulfhydryl groups to form cross-linked proteins. Therefore, the formation 
of protein aggregates is a normal cellular process of aging. Normally, 
these proteins are cleared by the proteasome as they form, thus 
establishing a homeostasis. However, proteasome degradation of 
aberrant proteins requires ATP, which would exacerbate the energy 
requirement under oxidative stress. Under oxidative stress, cells such as 
neurons will slow down the mitochondria respiration to reduce the free 
radical production. At the same time, the proteasome requires additional 
ATP to degrade damaged proteins. These contradictions are resolved 
through the precipitation of damaged proteins to form tangles or plaques. 
However, the protein precipitation process requires an initiator. We 
suspect that a number of proteins act as such initiators, including α-
Fig. 5. TH induced aggregation of 
α-synuclein. α-Synuclein was 
mixed with TH in HEPES, pH 7.0 
buffer and incubated at 37oC with 
shaking (210 rpm) in the absence 
of reduced glutathione and the 
resulting samples were analyzed by 
SDS-PAGE. Alpha-synuclein was 
detected by western blot with anti-
synuclein monoclonal antibody 
(syn211). A, total reaction mixture; 
B, 30,000 x g pellet; the reaction 
mixtures were centrifuged at 
30,000g at 4oC and the pellets were 
washed three times with 1xPBS 
buffer. 
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synuclein, β-amyloid peptide, tau, and parkin. Of these proteins, α-synuclein plays the most important role, as it 
can initiate protein aggregation when its C-terminal tyrosine residues are oxidized to catechols by hydroxylases, 
such as tyrosine hydroxylase, phenylalanine hydroxylase, and possibly tryptophan hydroxylase. The aggregation 
of α-synuclein induced by tyrosine hydroxylase is shown in Fig. 5.  
 
The tendency of catechol-containing proteins to crosslink is used by many species to form plaques or glues for 
attachment43.  One interesting observation of the α-synuclein C-terminal sequence is its surprising similarity with 
the repeating sequence of mussel protein Dpfp1 (Fig.6). The tyrosine residues in Dpfp1 are hydroxylated to exert 
its cross-linking abilities for the formation of plaques44. In fact, purified Dpfp proteins from mussels 
spontaneously form high molecular weight aggregates45. It is interesting to note that Mpfp1 (also called Mefp1), 
like α-synuclein, has little defined secondary structure in vitro46. 
 
Therefore, the formation of protein tangles or plaques is a way to reduce energy expenditure by neurons. The 
process is similar to the formation of neuromelanin and melanin, as both pigments originate from catechols. 
Functionally, protein tangles and plaques also share similarities with neuromelanin. They are strong metal 
chelators, especially of ferrous and ferric ions, to sequester them from cytosol. Overall, instead of serving as 
initiators of neurodegeneration, we believe that the formation of protein tangles and plaques are the results of a 
protective mechanism in response to persistent oxidative stress. 
 
 
 
CONCLUDING REMARKS 
 
Despite herculean efforts from researchers across academics and industry, the cure for AD has been elusive. In 
fact, clinical trials based on the β-amyloid hypothesis have not been successful so far. It is time to try alternative 
hypotheses and adopt different approaches for the development of AD treatment options. The hypothesis that 
neurodegeneration originates from metabolic imbalance or overactive immune system is supported by numerous 
studies including epidemiology studies showing47, 48that patients with type II diabetes display increased risk of 
AD. The recent genome wide association studies also identified that cholesterol metabolism and immune system 
are implicated in the etiology of AD49, 50. Taking together, adjustments to development plans are warranted, 
especially for the pharmaceutical industry that invests heavily in the advancement for AD treatments. 
 
Correspondence: Zhongtao_zhang@nymc.edu 
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